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Background: Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging
(MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative
(ER-positive/HER2-negative) breast cancer. We estimated the expected cost-effectiveness and resources required
for its implementation compared to conventional-NACT.
Methods: A Markov model compared costs, quality-adjusted-life-years (QALYs) and costs/QALY of RG-NACT vs.
conventional-NACT, from a hospital perspective over a 5-year time horizon. Health services required for and health
outcomes of implementation were estimated via resource modelling analysis, considering a current (4 %) and a full
(100 %) implementation scenario.
Results: RG-NACT was expected to be more effective and less costly than conventional NACT in both
implementation scenarios, with 94 % (current) and 95 % (full) certainty, at a willingness to pay threshold of €20.000/
QALY. Fully implementing RG-NACT in the Dutch target population of 6306 patients requires additional 5335 MRI
examinations and an (absolute) increase in the number of MRI technologists, by 3.6 fte (full-time equivalent), and of
breast radiologists, by 0.4 fte. On the other hand, it prevents 9 additional relapses, 143 cancer deaths, 23 congestive
heart failure events and 2 myelodysplastic syndrome/acute myeloid leukaemia events.
Conclusion: Considering cost-effectiveness, RG-NACT is expected to dominate conventional-NACT. While personnel
capacity is likely to be sufficient for a full implementation scenario, MRI utilization needs to be intensified.
Keywords: Cost-effectiveness, Resource utilization, Breast cancer, Neoadjuvant chemotherapy,
Response monitoring, MRIBackground
Neoadjuvant (preoperative) chemotherapy (NACT) is
equally effective as adjuvant chemotherapy in breast can-
cer [1], while offering the possibility of tailoring therapy
based on tumour response at monitoring [2]. Among
non-invasive imaging modalities for response monitoring,
contrast-enhanced magnetic resonance imaging (MRI) is
generally regarded as the most accurate for invasive breast* Correspondence: w.v.harten@nki.nl
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response (pCR), the most reliable surrogate endpoint of
survival [3–5].
Researchers in the Netherlands Cancer Institute (NKI)
have previously published criteria for monitoring NACT
response with MRI [6]. The research confirmed its predic-
tion for pCR in the triple negative breast cancer subtype
[7], but not in oestrogen receptor-positive (ER+) and
epidermal growth factor receptor 2- negative (HER2-)
tumours. This was not an unexpected finding, given the
known low rates of pCR in ER-positive/HER2-negative
tumors [8, 9] make it an unsuitable measure of tumour
response in these tumours. Hence, to investigate theirle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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quent study from this group used serial MRI response
monitoring as a readout of response [10]. In this study, un-
responsive tumours to the first chemotherapy regimen were
switched to a second, presumably, ‘non-cross-resistant’ regi-
men. Upon study completion, the tumour size reduction
caused by the non-cross-resistant regimen was similar to
that in initially responding tumours after the first regimen.
Furthermore, relapse frequency in both groups was similar.
These observations suggested that ER-positive/HER2-nega-
tive tumours do benefit from RG-NACT with MRI, despite
not reaching pCR. These results are in line with those from
the German Breast Group [11], which also showed survival
advantage from RG-NACT in ER+ patients.
Compared to traditional NACT, RG-NACT has thus
shown to positively influence ER-positive/HER2-negative
patients’ survival, yet comes at additional monitoring
costs. Its onset costs may however be offset by a reduc-
tion in the subsequent medical costs. This can be ex-
plored via probabilistic cost-effectiveness analysis (CEA),
which quantifies the probability and extent to which RG-
NACT is expected to be cost-effective compared to con-
ventional NACT as based on current evidence. Such infor-
mation is of interest for health-care regulators who, under
the pressure of limited resources, are increasingly using
cost-effectiveness as a criterion in decision-making [12].
An important goal for decision-makers is the implemen-
tation of cost-effective health-care interventions into rou-
tine clinical practice. Yet this can often be jeopardized by
the lack of attention given to resource demands [13]. Im-
plementation as described in a CEA may not always be
feasible, as this assumes that all physical resources (i.e., doc-
tors, scanners, drugs) required by the new strategy are im-
mediately available, regardless of actual supply constraints
(or likely demand). Ignoring these constraints may result in
negative consequences, from low levels of implementation
through to the technology not being implemented at all
[13]. Resource modelling is a method that quantitatively
captures the resource implications of implementing a new
technology. While this approach has scarcely been used in
health-care decision-making, it can be of great help to
health services planners who are challenged by implemen-
tation issues normally not addressed in CEAs.
Our aim is thus to estimate the expected cost-
effectiveness and resource requirements of imple-
menting RG-NACT with MRI for the treatment of
ER-positive/HER2-negative breast cancers using The
Netherlands as a case study population.Methods
This study followed the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist and
did not require ethical approval [14].Treatment strategies
Two strategies were considered for the treatment of ER-
positive/HER2-negative breast cancer women; RG-NACT
and conventional-NACT (Fig. 1). RG-NACT followed our
single-institution neoadjuvant chemotherapy program [10]:
treatment with NACT 1 (AC, doxorubicin 60 mg m − 2
and cyclophosphamide 600 mg m − 2 on day 1, every
14 days, with PEG-filgrastim on day 2) for three courses
(3x) followed by MRI scanning and subsequent classifica-
tion into ‘favourable’ or ‘unfavourable’ responders to NACT
defined by previously published criteria [6]. In short, reduc-
tion of more than 25 % in the largest diameter of the
tumour at late enhancement on the interim MRI relative to
the baseline MRI was regarded as a ‘favourable’ response.
All other responses were classified as ‘unfavourable’.
Favourable patients continue with additional 3×NACT 1,
and unfavourable patients switch to 3×NACT 2 (DC, doce-
taxel 75 mg m − 2 on day 1, every 21 days and capecitabine
2 × 1000 mg m − 2 on days 1–14). Conventional-NACT
represented current practice: treatment with 6×AC. Follow-
ing NACT, all patients underwent surgery, radiation ther-
apy when indicated and at least 5-years of endocrine
treatment according to protocol.
Implementation scenarios
We performed the cost-effectiveness and resource
modelling analysis for two implementation scenarios in
the Netherlands, i.e. current implementation and full im-
plementation. These scenarios were adopted in a hypo-
thetical cohort of 6306 patients, reflecting the Dutch
target population of stage II/III ER-positive/HER2-nega-
tive breast cancers. These are patients with the same
baseline characteristics as those of our neoadjuvant
chemotherapy program, and thus, where RG-NACT
seems beneficial [10]. The current implementation sce-
nario is defined as the number of stage II/III ER-
positive/HER2-negative breast cancer patients currently
treated with RG-NACT divided by all stage II/III ER-
positive/HER2-negative breast cancer patients. The full
implementation scenario considers the use of RG-NACT
in the entire stage II/III ER-positive/HER2-negative
breast cancer population. Although this is not entirely
likely, there is always a percentage of non-compliant
providers, we decided to present the maximum possible
resource use of RG-NACT. The number of patients
currently treated with RG-NACT was calculated as the
number of scans performed in the Netherlands (assum-
ing 1 scan/patient) [15] minus the number of scans
performed for other disease areas than oncology [16],
other cancers than breast [17], other applications than
guiding response to therapy [18], other stages than II/III
[19], and other receptor expressions than ER-positive/
HER2-negative [20]. The entire stage II/III ER-positive/
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Fig. 1 Decision analytic model to compare the health-economic outcomes of treating ER-positive/HER2-negative stage II-III breast cancer patients
with response-guided NACT vs. conventional-NACT. Decision nodes (■); patient or health provider makes a choice. Chance nodes (●); more
than one event is possible but is not decided by neither the patient or health provider. Abbreviations: NACT = neoadjuvant chemotherapy;
RFS = relapse free survival; DFS = disease free survival; R = relapse; D = death; AC = cyclophosphamide, doxorubicine; DC = docetaxel, capecitabine
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Netherlands (The Netherlands Cancer Registry) by the
proportion of patients with stage II/III ER-positive/HER2-
negative breast cancer (calculations presented in Table 1).
Model overview
We developed a Markov model to estimate mean dif-
ferences in clinical effects and costs of treatment with
RG-NACT vs. conventional-NACT from a Dutch hos-
pital perspective. For each treatment strategy, the
model simulated the transitions of a hypothetical co-
hort of stage II/III ER-positive/HER2-negative breast
cancer patients of 50 years old over three health-
states: disease free (DFS), relapse (R, including local,
regional and distant) and death (D, including breast
cancer and non-breast cancer), during a 5-year time
horizon (Fig. 1). The model was programmed in
Microsoft Excel (Redmond, Washington: Microsoft,
2007. Computer Software).
Upon completion of the NACT intervention, patients in
each cohort entered the model in the DFS state (Fig. 1).
Patients treated under the RG-NACT strategy entered
the DFS model state classified as true-favourable, true-
unfavourable, false-favourable and false-unfavourable
respondents of NACT at monitoring by using the 5-year
RFS (relapse free survival) as the “gold standard” for
NACT response. This was considered a sensibleassumption to capture all relapses related to NACT
response [21]. Definitions for true-favourable, true-
unfavourable, false-favourable and false-unfavourable
respondents are presented in Table 2.
In year 1 of the DFS health-state, patients were attrib-
uted the costs and health related quality-of-life (HRQoL)
of the NACT intervention, except when there was an inci-
dental MRI finding or when they suffered from
chemotherapy-related toxicities (Terminology for Adverse
Events grades 3 and 4 [22]); vomiting, neutropenia, hand-
foot-syndrome (HFS), desquamation and congestive heart
failure (CHF) [23, 24]). In these situations, there was
NACT interruption and temporary changes in costs and
HRQoL, except for HFS and desquamation. For these
toxicities there is no other curative treatment than
time, thereby, they were exempt of costs. From the
DFS health-state, patients could either move to the R
health-state, i.e., ‘relapse event’; move to the D health-
state, i.e., ‘non-breast cancer death event’; or stay in the
DFS health-state, i.e., ‘no event’. From the R health-state,
patients could either move to the D health-state, i.e.,
‘breast cancer or non-breast cancer related death event’;
or stay in the R health-state, i.e., ‘cured relapse’. We
assumed that patients could only develop one relapse. In
the 5th-year of the model, patients could incur long-term
NACT-related toxicities, including myelodysplastic syn-
drome (MDS) and acute myeloid leukaemia (AML) [25].
Table 1 Current implementation scenario calculation [15–20, 54]
=
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Input model parameters are presented in Table 3.
Clinical
The proportions of favourable and unfavourable patients
at monitoring and after 5-years of NACT were retrieved
from an updated version of the individual patient data
from Rigter et al. [10]. The transition probabilities (tp)
simulating a relapse and a breast cancer death event
were derived from Kaplan-Meyer (KM) curves. The first
from a KM of RFS (interval from finishing the NACT
intervention to occurrence of first relapse) and the sec-
ond, from a KM of breast cancer specific survival (BCSS;
interval from relapse to occurrence of breast cancer
death). The KMs were either constructed uniquely with
raw data of Rigter et al. [10], or by using additional
assumptions, which we explain in detail below. Calcula-
tions were performed in SPSS (IBM Corp. Released
2013. IBM SPSS Statistics for Windows, Version 22.0).
RG-NACT: The tps for the group of false-unfavourable
and false-favourable patients were derived by using KMs
and the formula tp(tu) = 1 − exp{H(t − u) −H(t)} [26],
where u is the length of the Markov cycle (1 year) and H
is the cumulative hazard. Data for the KM of RFS came
from 25 relapsed patients from Rigter et al. [10], and
that of BCSS, from literature [27]. The tps of relapse and
breast cancer death for the true-favourable and true-
unfavourable patients were assumed to be zero at all times,
as these patients do not relapse nor die from breast cancer(see Table 2). Conventional-NACT: tps were derived from
KM curves, with data from the complete dataset of Rigter
et al. [10] for the RFS curve and data from literature [27]
for the BCSS curve. The formula to derive tps was:
tp(tu) = 1 − exp{1/τ(H(t − u) −H(t))} [26], where τ is the
treatment effect or hazard ratio (HR) of RG-NACT vs.
conventional-NACT. This formula allowed calculating
the tps from a “hypothetical” control arm, which was
inexistent in the Rigter et al. [10] study. The used HRs
were 0.5 for the RFS curve, and 0.6 for the BCSS curve.
Both HRs were derived from literature. They were set
equal to the reported HR of DFS and OS in a similar
population of ER-positive breast cancers where RG-
NACT vs. conventional-NACT was being compared [11].
As these assumptions could affect our cost-effectiveness
results, we performed a one-way and two-way sensitivity
analysis (SA) to the HRs (range 0.1 - 1.5).
The tps of non-BC related deaths (i.e., transition from
any state to D) were accounted for by using Dutch life
tables [28]. The occurrence of vomiting, neutropenia, HFS
and desquamation under 3×AC and 3×DC, were derived
from literature [24]. When a patient received both 3×AC
and 3xDC the probability of vomiting and neutropenia
was represented as the combined probability of two inde-
pendent events (P(A and B) = P(A) * P(B)). The probability
of occurrence of CHF due to the administration of anthra-
cyclines was accounted for in the 1st-year of the model
and was dose-dependent: 0.2 % with 3×AC and 1.7 % with
6xAC [23]. Also the probability of incidental findings at
Table 2 Definitions of true-favourable, false-favourable,
true-unfavourable and false-unfavourable used in our study
Group of patients Definition
True favourable Patient that is classified as favourable at monitoring
(criteria [7]), continues receiving NACT 1, and after
5 years of follow up is classified as favourable due
to absence of relapse event
False favourable Patient that is classified as favourable at monitoring
(criteria [7]), continues receiving NACT 1, and after
5 years of follow up is classified as unfavourable
due to presence of relapse event
True unfavourable Patient that is unfavourable at monitoring
(criteria [7]), switches to NACT 2, and after 5 years
of follow up is classified as favourable due to absence
of relapse event (the underlying assumption is that the
patient was not responding to NACT1 but did to NACT 2,
thereby demonstrating that monitoring classified the
patient properly)
False unfavourable Patient that is unfavourable at monitoring
(criteria [7]), switches to NACT 2, and after 5 years
of follow up is classified as unfavourable due to
presence of relapse event (the underlying
assumption is that the patient was responding
to NACT1 and did not to NACT 2, thereby
demonstrating that monitoring classified
the patient wrongly)a
aAlthough we are aware that in the ‘False favourable’ group there could be
patients irresponsive to both NACT 1 and 2, as the design of the RG-NACT
does not allow distinguishing them, we had to make such an assumption
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MDS and AML events was based on cumulative doses of
anthracycline and cyclophosphamide [25]. Patients whose
NACT was interrupted to treat toxicities were still as-
sumed to benefit from NACT and the same relapse rate
was applied.
Costs
Intervention costs comprise of chemotherapy, monitoring,
chemotherapy-related toxicities and costs of confirming
incidental findings. To calculate drug dosages we assumed
patients of 60Kg and body-surface area of 1.6 m2. Drug
use was derived from study protocol, and costed by using
literature [30, 31] and Dutch sources on costs and prices
(Dutch National Health Care Institute; Dutch Healthcare
Authority; Dutch Health Care Insurance Board). Chemo-
therapy costs included day care and one visit to the on-
cologist per cycle. Costs of monitoring consisted of one
MRI scan [32] and one medical visit of 1 h (accounting for
waiting time) [31]. Costs of treating toxicities were taken
from literature [33–35]. Costs of confirming incidental
findings were estimated as an average of “standard diagnos-
tic imaging” (i.e., Ultrasound, x-Ray and bone scintigraphy)
using prices from the ‘The Nederlandse Zorgautoriteit’
(Dutch Healthcare Authority) as a proxy [32]. Health state
costs, i.e., follow up costs for the DFS health state and de-
tection plus treatment costs for the R health state, were de-
rived from literature [36]. All results were reported in 2013Euros, using exchange currencies [37] and the consumer
price index to account for inflation [38].
Health-Related Quality of life
Utilities were derived from published literature. The
DFS utility was 0.78 except in the 1st-year cycle when
patients either accrued the utility of the NACT
regimen without toxicities i.e., 0.62 [39], the utility of
the NACT regimen with toxicities i.e., 0.62 minus the
utility decrements [40–42]) or the utility of anxiety in
patients were incidental findings at MRI occurred i.e.,
0.68 [43]. These utilities lasted for the whole cycle. The
R utility was calculated as an average of the utility of
local and distant relapse [39]. All utility weights were
obtained from sources using the EuroQoL EQ-5D
questionnaires, except anxiety, which was derived from
a Quality of Well-Being index [43]. There is no litera-
ture to suggest an effect of monitoring on HRQoL,
thus this was assumed unaltered.
Scenarios and resource modelling
Additional parameters to simulate the scenarios and to
perform the resource modelling exercise were added in the
model. These include a parameter reflecting the RG-
NACT uptake, and parameters illustrating the proportion
of i) patients with MRI contraindications (impaired renal
function due to the risk of developing Nephrogenic Sys-
temic Fibrosis (NSF) [44], presence of ferrous body parts
like peacemaker (mean of values reported in [45–47], and
claustrophobia [48]), ii) patients with NSF [49], iii) patients
with malignant incidental findings [30] and iv) MRI tech-
nologists with acute transition symptoms (ATS) [50].
Cost-effectiveness analysis
The 5-year cumulative outcomes (health benefits and
costs) were simulated for a cohort of 6306 individuals. The
cost-effectiveness outcome measure was the incremental
cost-effectiveness ratio (ICER), which is the difference in
expected costs (per patient) divided by the difference in
expected effects expressed as (quality-adjusted) life-years
((QA)LYs)) of treating one hypothetical cohort with RG-
NACT vs. treating an identical cohort with conventional-
NACT. For the current implementation scenario, we com-
pared the expected costs and QALYs of a cohort as treated
with conventional-NACT, to the costs and QALYs of a
cohort partially treated with RG-NACT, as dictated by the
implementation rate and MRI contraindications. Patients
where RG-NACT was not implemented or MRI was con-
traindicated were modelled as receivers of conventional-
NACT. The full implementation scenario was modelled in
the same way, except that the RG-NACT strategy was now
applied to all patients in the cohort, except those with MRI
contraindications receiving conventional-NACT.
Table 3 Input model parameters
Parameter mean SE Parametersa Distribution Source
Clinical data
Monitoring performanceb (proportions)
True favourable 0,53 0,04 0,53/0,04 Dirichlet [10]
True unfavourable 0,24 0,05 0,24/0,05 Dirichlet [10]
False favourable 0,17 0,07 0,17/0,07 Dirichlet [10]
False unfavourable 0,07 0,09 0,07/0,09 Dirichlet [10]
Chemotherapy related toxicities
Vomiting 3×AC 0,05 0,02 5/98 beta [24]
3×DC 0,24 0,04 24/77 beta [24]
HFS 3×DC 0,22 0,04 23/80 beta [24]
Neutropenia 3×AC 0,85 0,04 86/15 beta [24]
3×DC 0,72 0,04 74/29 beta [24]
Desquamation 3×DC 0,05 0,02 5/98 beta [24]
CHF 3×AC 0,002 0,20 1/359 beta [23]
6×AC 0,02 0,60 11/349 beta [23]
AML/MDS 3×AC 0,003 0,001 12/4471 beta [25]
6×AC 0,005 0,001 12/2372 beta [25]
Transition probabilities
Relapse
RG-NACT; False favourable/unfavourable Tp1 0,14 0,06 4/24 beta [10]
Tp2 0,29 0,08 8/20 beta [10]
Tp3 0,47 0,09 13/15 beta [10]
Tp4 0,44 0,09 12/16 beta [10]
Tp5 0,40 0,09 11/17 beta [10]
RG-NACT; True favourable/unfavourable Tp12-5 0,00 NA - fixed assumption
HR RFS (RG-NACT vs. conventional-NACT) 0,50 0,20 0,50/0,20 Normal truncated assumption
Conventional-NACT Tp1 0,03 - - - [10]
Tp2 0,06 - - - [10]
Tp3 0,08 - - - [10]
Tp4 0,05 - - - [10]













Table 3 Input model parameters (Continued)
Breast cancer specific death
False favourable/unfavourable Tp1 0,00 NA - fixed assumption
Tp2 0,04 0,02 5/109 beta [27]
Tp3 0,12 0,03 14/100 beta [27]
Tp4 0,06 0,02 7/107 beta [27]
Tp5 0,19 0,04 22/92 beta [27]
HR BCSS (RG-NACT vs. conventional-NACT) 0,64 0,13 0,64/0,13 normal [11]
Conventional-NACT Tp1 0,00 NA - fixed assumption
Tp2 0,06 - - - [27]
Tp3 0,19 - - - [27]
Tp4 0,09 - - - [27]
Tp5 0,28 - - - [27]
Utilities
Chemotherapy 0,62 0,04 94/58 beta [39]
Neutropenia 0,53 0,01 557/488 beta [40]
Anxiety 0,68 0,06 40/19 beta [43]
Vomiting 0,52 0,08 17/16 beta [41]
HFS 0,50 0,10 12/12 beta [41]
Desquamation 0,59 0,01 1041/721 beta [40]
CHF (average grade III/IV) 0,55 - - beta [42]
CHF grade III 0,59 0,02 360/250 beta [42]
CHF grade IV 0,51 0,05 52/50 beta [42]
MDS/MLA 0,26 0,01 500/1423 beta [55]
DFS 0,80 0,03 196/49 beta [39]
R (average loco-regional and metastatic) 0,73 - - beta [39]
Loco-regional relapse 0,68 0,03 226/104 beta [39]
Metastatic relapse 0,78 0,04 104/30 beta [39]
Scenarios and resource modelling
Incidental findings
All 0,18 0,01 270/1265 beta [29]
Malign 0,20 0,02 55/270 beta [29]
MRI contraindications













Table 3 Input model parameters (Continued)
Gadolinium allergy 0.0003 0.01d 0.08/29 - [44]
Body ferrous parts 0.58 0.1 0.26/4.21 beta [45]
Claustrophobia 0.02 0.1 0.02/0.94 beta [48]
Uptake 0.04 20-100 % fixed assumption
MRI technologists with ATS 0.26 - fixed [50]
Costs
Parameter Unit costs Unit measure Mean resource use Mean cost SEe Distribution Source
Chemotherapy
6×AC Doxorubicin €204 90 mg 5,3 €1306 €326 Gamma [31]
Cyclophosphamide €45 1080 mg 6,4 €239 €60 Gamma [31]
Peg-filgrastim €849 1 mg 6 €5096 €1274 Gamma [56]
Pharmacy preparation €45 Per course 6 €267 67 Gamma NKI
Day care €286 Day 6 €1718 €430 Gamma [30]
Oncologist’s visit €109 Visit 6 €653 €163 Gamma [31]
Total €9279
3×AC/3×DC Doxorubicin €204 90 mg 3,2 €653 €163 Gamma [31]
Cyclophosphamide €45 1080 mg 2,7 €120 €30 Gamma [31]
Peg-filgrastim €849 1 mg 3 €2548 €637 Gamma [56]
Docetaxel €959 108 mg 3,3 €3195 €799 Gamma [31]
Capecitabine €27 4500 mg 29,9 €821 €205 Gamma [31]
Pharmacy preparation €45 Per course €267 €67 Gamma NKI
Day care €286 Day 6 €1718 €430 Gamma [30]




Hospital costs €163 Scan 1 €163 €41 Gamma
Specialists fees €52 Scan 1 €52 €13 Gamma
Total €215
Confirm incidental findings €149 Episode 1 €149 €37 Gamma
Chemotherapy related toxicities
Neutropenia €14397 Episode 1 €14397 €425 Gamma [35]













Table 3 Input model parameters (Continued)
CHF €18225 Episode 1 €18225 €4556 Gamma [33]
MDS/MLA €112946 Episode 1 €112946 €28236 Gamma [58, 59]
Health states
DFS In & out –patient €2793 Episode 1 €2793 €563 Gamma [36]
Drugs €79 Episode 1 €79 €20 Gamma [36]
Total €2872
R Local relapse
In & out -patient €12497 Episode 1 €12497 €1692 Gamma [36]
Drugs €2336 Episode 1 €2336 €584 Gamma [36]
Distant metastasis
In & out -patient €11645 Episode 1 €11645 €1346 Gamma [36]
Drugs €5772 Episode 1 €5772 €1443 Gamma [36]
Total €16125
BC death €8296 Episode 1 €8296 €2074 Gamma [36]
Abbreviations: SE standard error, AC cyclophosphamide, doxorubicine; DC docetaxel, capecitabine; HFS hand-food-syndrome, CFH congestive heart failure, AML/ADM acute myeloid leukaemia/myelodysplastic syndrome,
MRI magnetic resonance imaging, tp transition probability, HR hazard ratio, RG-NACT response guided neoadjuvant chemotherapy, NACT neoadjuvant chemotherapy, DFS disease free survival, R relapse, RFS relapse free
survival, BCSS breast cancer specific survival, BC breast cancer, ATS acute transition symptom, NKI Netherlands Cancer Institute
aDirichlet distribution: mean/SE, Beta distribution: α/β, Normal distribution: mean/SE
bWe derived these proportions with the dataset of Rigter et al., as explained in the section ‘clinical input parameters’ and following the definitions of ‘Table 2’
cWe assumed a SE = 0.1
dWe assumed a SE = 0.01
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after assigning a distribution to each model parameter
following the recommendations by Briggs et al. [38]. A
beta distribution was assigned to binomial data such as
toxicities and transition probabilities, a dirichlet distribu-
tion to the proportions of true/false favourable/un-
favourable patients, and a gamma distribution to utilities
and costs (Table 3). The uncertainty surrounding the
model results was presented as cost-effectiveness accept-
ability curves (CEAC), which reflect the probability of
each alternative to be cost-effective across a range of
threshold values for cost-effectiveness. We discounted
future costs and health effects at a 4 % and 1.5 % yearly
rate respectively, according to the Dutch guidelines on
health-economics evaluations [51]. A strategy was con-
sidered cost-effective if the ICER did not exceed the
willingness-to-pay threshold of €20.000/QALY.
Resource modelling analysis
We estimated the health services required and the health
outcomes experienced in each strategy. Health services
required included: number of 1) MRI scans performed,
2) patients scanned per MRI, 3) Full-time equivalent
(FTE) MRI technologists, 4) FTE breast radiologists and
5) confirmation of incidental findings. Health outcomes
included: number of 1) relapses prevented, 2) breast can-
cer deaths prevented, 3) excluded patients due to contra-
indications, 4) patients with adverse events (including
NSF, CHF and AML/ADS), 5) patients with anxiety due
to incidental findings, 6) patients with malignant inci-
dental findings, and 7) fte MRI technologists with ATS.
These outcomes were analysed deterministically for the
current and full implementation scenarios and expressed
for the 6306 ER-positive/HER2-negative breast cancer
women. A detailed description of the calculations and
sources for each outcome is presented in (Table 4).
Volumes of health services needed were also calculated
at the hospital level, which required determining the num-
ber of hospitals expected to offer RG-NACT under each
scenario. For current implementation, we assumed RG-
NACT to be used in the 16 hospitals of the largest Dutch
hospital network currently involved in the RG-NACT trial
NCT01057069 (Clinical Trials.gov). Although this trial ex-
cludes ER+ patients, we expected involved hospitals to
have endorsed RG-NACT in other subtypes with single
institution studies, as is the case in the NKI. For the
full implementation, we considered all 113 hospitals
(locations) with MRI that deliver cancer treatment (i.e.,
university, general and specialized hospitals), as identi-
fied from the database published by the National Public
Health Atlas [52]. The presence and quantity of MRI
scans per hospital was either taken from that hospital’s
website or based on literature [50], indicating 3 MRIs
per academic hospital and 1 per general hospital.As increasing RG-NACT uptake from 4 to 100 % is
not realistic in a short time-frame, we explored the re-
source requirements and health outcomes across a range
of implementation rates via one-way SA including 20,
40, 60 and 80 % uptake.
All assumptions made were confirmed by an experi-
enced MRI technologist in a general hospital. One-way
SAs on one key-assumptions was done: ‘the time re-
quired by a breast radiologist for MRI scan interpret-
ation’ (range 6.8–15 min).
Results
Cost-effectiveness analysis
At current implementation (4 %) RG-NACT was ex-
pected to result in 0.005 QALYs gains and savings of €13
per patient. Under full implementation, RG-NACT is ex-
pected to generate 0.12 additional QALYs and savings of
€328 per patient (Table 5). In both scenarios, RG-
NACT is expected to dominate (be more effective and
less costly) than conventional-NACT. The results of
the PSAs show that at a willingness to pay threshold of
€20.000/QALY, RG-NACT is expected to be the opti-
mal strategy under the current and full implementation
scenarios, with 94 and 95 % certainty respectively
(Fig. 2).
SAs of RFS and BCSS hazard ratios (baseline values of
0.5 and 0.64 respectively), invariably showed the RG-
NACT strategy to be cost-effective (Table 4). Even when
LYs were slightly higher in the conventional-NACT arm
(i.e., with HRs of >1), the better quality of life provided
by the DC treatment of the RG-NACT strategy (lower
and better tolerated adverse events) maintained the in-
cremental QALYs for the RG-NACT strategy.
Resource modelling analysis
Under the current implementation scenario we calcu-
lated that over 5-years, the RG-NACT strategy requires
218 MRI scans to be performed in the target population
of 6306 women, after 40 exclusions due to contraindica-
tions. With 31 MRI scans currently used for this purpose
(estimated number of MRI scans in the multicentre
NCT01057069 trial), 7 patients were scanned/MRI, re-
quiring a total of 0.2 fte MRI technologists and 0.02 fte
breast radiologists. At the hospital level covering a
population of 6306 breast cancers, 14 MRI scans would
be required for the prevalent population over a 5-year
timeframe. Assuming an average capacity of 2 MRI
scans/hospital (estimated weighted average of MRI
scans/hospital within the multicentre NCT01057069
trial), this would translate to 7 patients scanned/MRI,
demanding 0.01 fte MRI technologists and 0.001 fte
breast radiologists per hospital. In terms of health out-
comes, the current implementation scenario was ex-
pected to prevent 0.4 relapses and 6 breast cancer
Table 4 Resource modelling outcomes, sources and calculations
Current implementation
(16 hospitals, 31 MRIs)
Full implementation
(113 hospitals, 148 MRIs)
Source
Health services required at the country level
No of MRIs scans performed Calculations in Table 2 No of stage II-III, ER-positive/HER2-negative
breast cancers in the Netherlands
See Table 2
No of patients scanned per MRI ‘No of MRI scans performed’/31 MRIsa ‘No of MRI scans performed’/148 MRIsa See
footnote a
Fte MRI technologists required Yearly hours required of MRI technologist to perform
the ‘No of MRIs scans performed’/Fully workable
hours of an MRI technologist a yearb
idem See
footnote b
Fte breast radiologists required Yearly hours required of breast radiologist to perform
the ‘No of MRIs scans performed’/Fully workable
hours of a breast radiologist a yearc
idem See
footnote c
No of confirmations of incidental
findings (using standard imaging)
Derived from the Markov model idem -
Health services required at the hospital level
No of MRIs scans performed per
hospital
‘No of MRI scans performed’/16 hospitalsd ‘No of MRI scans performed’/113 hospitalse See
footnote d
and e
No of patients scanned per MRI per
hospital
‘No of MRI scans performed per hospital’/mean
MRIs per hospitala
‘No of MRI scans performed per hospital’/
mean MRIs per hospitala
See
footnote a
Fte MRI technologists required per
hospital
Yearly hours required of MRI technologist to perform
the ‘No of MRI scans performed per hospital’/Fully
workable hours of an MRI technologist a yearb
idem See
footnote b
Fte breast radiologists required per
hospital
Yearly hours required of breast radiologist to perform
the ‘No of MRI scans performed per hospital’/Fully
workable hours of a breast radiologist a yearc
idem See
footnote c
Health outcomes gained at the country level
No of relapses prevented Derived from the Markov model idem -
No of breast cancer deaths prevented Derived from the Markov model idem -
Health outcomes lost at the country level
No of excluded patients due to
contraindications
Derived from the Markov model idem -
No of patients with NFS ‘No of MRI scans performed’* p of NSF idem [48]
Fte MRI technologists with ATS ‘Fte MRI technologists required’* p of ATS idem [49]
No of patients with CHF Derived from the Markov model idem -
No of patients with long term AML/
ADS
Derived from the Markov model idem -
No of patients with anxiety due to
incidental findings
Derived from the Markov model idem -
No of patients with malignant
incidental findings
‘No of confirmations of incidental findings’
*p malignant incidental findingsf
idem [28]
Abbreviations: No number, Fte full-time equivalent, MRI magnetic resonance imaging, RG-NACT response guided neoadjuvant chemotherapy; p probability, NSF
nephrogenic systemic fibrosis, ATS acute transient symptom, CHF chronic heart failure, DSF disease free survival, R relapse, AML/ADS myelodysplastic syndrome/
acute myeloid leukaemia
Note that when a calculation refers to another outcome of the table this is always the outcome within the same column i.e., within the same implementation rate
Idem means calculated equal as the left cell, but adapted to the full implementation scenario figures
aWe search for this information in each hospital website. When this information was not available or unclear, we made use of literature [49] where the most
frequent quantity of MRIs per type of hospital is presented (three for academic hospitals and one for general hospitals)
bHours required of MRI technologists for the ‘No of MRIs scans performed (per hospital)’ in a year are calculated by assuming that a full scanning procedure
requires 1 h of MRI technologist. Employees were assumed to work 52 weeks/year, 5 days/week i.e., 260 days/year. Of these, 40 days would be vacation and sick
days, resulting thus in 220 workable days/year. Assuming workers are employed for 8 h/day this results in 1760 working hours/year. Yet workers need some time
off during their working days i.e., breaks, assumed to be 20 %. Thereby, a fully workable year is of 1408 h
cHours required of breast radiologist for the ‘No of MRIs scans performed (per hospital)’ in a year are calculated by assuming a mean of 6.8 min needed for a
breast radiologist to interpret one MRI scan [53]. The workable hours a year of a breast radiologist were calculated exactly as explained in footnote 2
dAssuming its use in the biggest Dutch hospital network involved in RG-NACT (see ‘resource modelling analysis’ section)
eAssuming its use in all Dutch hospitals (locations) with MRI expected to deliver cancer treatment (i.e., university, general and specialized hospitals)
(see ‘resource modelling analysis’ section)
fAfter confirming by ultrasound
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Table 5 Resource modelling and cost-effectiveness results for the current and full implementation scenarios of response-guided
NACT in the Netherlands
Cost-effectiveness analysis expressed per patient
Current implementation (4 %) Full implementation (100 %)
Costs (€) LYs QALYs Δ costs (€) Δ QALYs ICER Costs (€) LYs QALYs Δ costs (€) Δ QALYs ICER
RG-NACT disc 28013 4.58 3.46 −13 0.005 dominanta 27698 4.64 3.58 −328 0.12 dominant
RG-NACT undisc 30362 4.79 3.62 −14 0.005 dominant 30021 4.85 3.74 −355 0.13 dominant
Conventional-NACT disc 28026 4.58 3.45 - - - 28026 4.58 3.45 - - -
Conventional-NACT undisc 30377 4.76 3.61 - - - 30377 4.76 3.61 - - -
One-way and two-way sensitivity analysis
ICER ICER ICER



















Resource modelling analysis expressed in relation to the Dutch population of ER-positive/HER2-negative breast cancer women (n = 6306)c
Current implementation
(16 hospitals, 31 MRIs)
Full implementation
(113 hospitals, 148 MRIs)
Transition from current to
full implementation
Health services required at the country level
No of MRIs scans performed 218 5335 +5117
No of patients scanned per MRI 7 36 +29
Fte MRI technologists 0.2 3.8 +3.6
Fte breast radiologists 0.02 0.4 +0.4
0.04b (↑121 %) 0.95b (↑121 %)
No of confirmations of incidental findings
(using standard imaging)
38 939 +901
Health services required at the hospital level
No of MRIs scans performed per hospital 14 47 +33
No of patients scanned per MRI per hospital 7 36 +29
Fte MRI technologists per hospital 0.01 0.03 +0.02
Fte breast radiologists per hospital 0.001 0.004 +0.003
0.002b (↑121 %) 0.001b (↑121 %)
Health outcomes gained at the country level
No of relapses prevented 0.4 9 +9
No of breast cancer deaths prevented 6 149 +143
Health outcomes lost at the country level
No of excluded patients due to contraindications 40 971 +931
No of patients with NFS 0.07 2 +2
Fte MRI technologists with acute transient symptom 0.04 0.9 +1
No of patients with CHF 106 83 −23
No of patients with long term AML/ADS 23 21 −2
No of patients with anxiety due to incidental findings 38 939 +901
No of patients with malignant incidental findings 8 192 +184
Abbreviations: Disc discounted, undisc undiscounted, No number, Fte full-time equivalent, MRI magnetic resonance imaging, NSF nephrogenic systemic fibrosis,
ATS acute transient symptom, CHF chronic heart failure, AML/ADS myelodysplastic syndrome/acute myeloid leukaemia
aRG-NACT is more effective and less costly than conventional NACT
bif radiologists spent 15 min to interpret 1 MRI scan
cWhen possible, figures were rounded to the nearest whole number



























Willingness to pay for QALY ( )
RG-NACT current implementation rate
RG-NACT full implementation rate
Conventional-NACT current implementation rate
Conventional-NACT full implementation rate
Fig. 2 Cost effectiveness acceptability curves. At a willingness to pay threshold of €20.000/QALY, RG-NACT is expected to be the optimal strategy
with 94 and 95 % certainty under the current and full implementation scenarios respectively
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106 patients would have a CHF, 23 patients would suf-
fer from AML/ADS and 38 incidental findings were
expected, of which 8 would be malignant. Of the re-
quired 0.2 fte MRI technologists, 0.04 fte would suffer
from ATS (Table 4).
Under the full implementation scenario, we calculated
that 5335 MRI scans would be needed over a 5-year
period for the 6306 pertinent breast cancer population,
after excluding 971 patients for contraindications. With
148 MRI scans available (estimated number of MRI
scans in the estimated 113 hospitals), this would require
36 patients to be scanned/MRI for which 3.8 fte MRI
technologists and 0.4 fte radiologists are needed. At the
hospital level, 47 MRI scans are expected to be performed
for the prevalent population of 6306 within 5-years. As-
suming the mean MRI scans/hospital is 1.3 (estimated
weighted average of MRIs/hospital within the estimated
113 hospitals), 36 patients would be scanned per MRI,
requiring 0.03 fte MRI technologists and 0.004 fte
breast radiologists per hospital. In terms of health out-
comes, the full implementation scenario was expected
to prevent 9 relapses and 149 breast cancer deaths, but
to bring about 2 patients with NSF, 83 patients with
CHF and 21 patients with AML/ADS. Furthermore,
there are 939 incidental findings expected, of which
192 would be malignant, and 0.9 fte MRI technologists
are projected to get ATS (Table 4).
The transition from current (4 %) to full (100 %) im-
plementation is expected to increase the number of ex-
aminations by 5117 (2347 %) countrywide or by 33(247 %) per hospital, consequently demanding an in-
crease of scan utilization (for an additional 29 patients),
an increase in the number MRI technologists by 3.6 fte
countrywide or by 0.02 fte per hospital, and a mar-
ginal increase in breast radiologists by 0.4 fte coun-
trywide or by 0.003 fte per hospital. In terms of
health outcomes, full implementation would diminish
the number of breast cancer related deaths and re-
lapses by 25-fold (from 6 to 149) and 23-fold (from
0.4 to 9) respectively, and the number of CHF and
AML/MDS by ~0.8-fold (from 106 to 83) and ~0.9-
fold (from 23 to 21) respectively. However, these
would come at the cost of a ~25-fold increase on
health losses (additional 2 patients with NSF, 1 fte
MRI technologist with ATS, 901 patients with anxiety due
to presence of incidental findings, and 184 patients with
confirmed malignant findings).
The one-way SA to the RG-NACT uptake rate
showed that increasing rates markedly increases the
number of patients with MRI contraindications, the
number confirmatory scans and the number of pa-
tients with anxiety while awaiting for those (Fig. 3).
Simultaneously, the number of cancer deaths, and the
number of patients with CHF and AML/ADS de-
creased consistently (by ~1.5, ~0.98 and ~0.95 -fold
per 20 % rate increase).
The results of the one-way SA on the radiologists’
working pattern assumption showed that increasing the
time required for MRI scan interpretation to 15 min,
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Implementation rate
No of MRI scans required
No of confirmations of incidental findings
Fte radiologists required














No of patients with MRI contraindications
No of patients with anxiety (incidental findings)
No of patients with malignant incidental findings
No of breast cancer deaths prevented
No of patients with CHF
Fte MRI technologists with ATS
No of patients with AML/ADM
No of relapses prevented
No of patients with NFS
a b
Fig. 3 Influence of implementation rates on resource modelling outcomes, (a) on health services required and (b) on health outcomes.
Abbreviations: No = number; Fte = full-time equivalent; MRI = magnetic resonance imaging; ATS = acute transition syndrome; CHF = chronic heart
failure; AML/ADM = acute myeloid leukaemia/myelodysplastic syndrome; NFS = nephrogenic systemic fibrosis
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The aim of our study was to estimate the cost-effectiveness
and resource requirements of implementing RG-NACT
with MRI for ER-positive/HER2-negative breast cancer
patients using The Netherlands as a case study population.
As RG-NACT is an emerging treatment approach and its
implementation is at its onset, we performed these analyses
under a current implementation scenario of 4 % uptake,
and under a full implementation scenario, to anticipate the
outcomes of a potential wider roll-out.
At the current 4 % uptake RG-NACT is expected to
be less expensive and achieve more QALYs than
conventional-NACT. With higher implementation rates,
more patients will be treated with this cost-saving and
effective strategy, rendering RG-NACT ever more dom-
inant. At full implementation, 0.12 additional QALYs
and savings of €328 per patient are expected. This is
achieved despite 15 % (971 out of the 6303 patients)
being treated with conventional-NACT due to MRI
contraindications. In both scenarios, decision uncer-
tainty surrounding the ICERs is low (~5 %).
The main drivers of advantageous survival in the RG-
NACT are the HRs used to derive the hypothetical survival
of the conventional-NACT strategy. Either of the HRs used
(for RFS and BCSS) was below 1, thus implying less breast
cancer related events in the RG-NACT strategy compared
to the conventional-NACT strategy. These values were
based on best available data from the GeparTrio trial [11],
but this evidence is still preliminary. One- and two-way SA
of these HR values demonstrated that even when survival
was higher in the conventional-NACT strategy, the better
quality-of-life derived from DC treatment in the RG-NACT
strategy maintained the cost-effectiveness of RG-NACT.
The cost savings of RG-NACT hinge on a satisfactory
diagnostic performance of MRI. Under current diagnos-
tic performance, 79 % of patients would not yield anyevent in the RG-NACT strategy, compared to 76 % in
conventional-NACT. Although the prevention of these
events came at the costs of 30 % of patients receiving a
more expensive treatment than conventional-NACT
(>€695), as treating one relapse is even more expensive
(€16125), RG-NACT was still cost saving.
The resource modelling analysis showed that increas-
ing RG-NACT uptake rates from 4 to 100 % is expected
to increase the number of examinations by 5117
(2347 %), consequently demanding a 5-fold increase in
scans utilization, a 19-fold increase in the number MRI
technologists and a 20-fold increase in the number of
breast radiologists. Thereby, adapting current practice to
meet these resources requires paying special attention to
the availability and utilization of MRIs, as well as avail-
ability of technical personnel. For instance, fully imple-
menting RG-NACT in the Netherlands, where 5701
MRI examinations were performed in 2013 (considering
843765 MRI examinations [15] performed in 148 MRIs),
would only require 2 days of additional MRI scanning
per year. However, current MRI utilization is already in-
tense; considering 1 scan lasts 1/2 h and the scan works
8 h/day, 843765 MRI examinations results in 356 days of
MRI scanning. As there are only 260 workable days a
year, hospitals had to intensify MRI’s use i.e., by adding
extra evening shifts. Hence, adding 2 extra days of scan-
ning a year would require of an even more intense MRI
utilization. In terms of personnel, the number of re-
quired MRI technologists and breast radiologists are not
expected to be a limiting implementation factor. While
fully implementing RG-NACT would require additional
2 fte MRI technologists and 1 fte breast radiologists to
the current 403 fte MRI technologists and 91 fte breast
radiologists required a year, availability is estimated to
be of 1700 MRI technologists countrywide [50] and 10
breast radiologists per hospital [53].
Miquel-Cases et al. BMC Cancer  (2016) 16:712 Page 15 of 17In terms of health outcomes gained, full implemen-
tation would diminish the number of breast cancer
related deaths and relapses by 25- and 23-fold
respectively, and the number of severe and costly
adverse events as CHF and AML/MDS by ~0.8- and
~0.9-fold respectively. However, these would come at
the cost of a parallel ~25-fold increase in patients
with NSF, MRI contraindications, MRI technologists
with ATS and incidental findings causing anxiety and
other diseases.
Our post-hoc analysis on resource requirements at
various RG-NACT implementation rates allow identify-
ing those that seem feasible given current resources.
Considering current MRI machines and personnel
capacity, RG-NACT implementation seems feasible at
any rate. However, it would be interesting to further
investigate whether there is sufficient capacity to
handle an increase of incidental findings (requiring
further diagnostic examinations), as well the cost-
consequences of treating those that are diagnosed as
malignant.
Our study has some limitations. A limitation of the
response-guided approach itself was the impossibility to
distinguish in the false-unfavourable group, patients truly
falsely classified at monitoring from patients irresponsive to
3×DC or NACT in general. Yet, as this is inherent to
guided-NACT, it was included as such in the model. Fur-
thermore, we did not consider adjuvant treatment in our
model, as the administration of this was similar between
arms. Moreover, we considered AC, instead of a 3rd
generation regimen containing taxanes as standard
treatment because it was considered the best com-
parator for the used RG-NACT regimens. As costs of
those are different, we performed a post-hoc one-way
SA and found that RG-NACT would become more
dominant due to increased cost savings. Additionally,
we only accounted for direct-medical costs as other
cost beyond the direct hospital-based treatment, such
as productivity losses or home health care exist, are
less likely to influence decision-making.
Conclusion
While the typical CEA assumes perfect implementation
of the strategy under investigation, we showed the
impact of implementation rates on incremental health
gains and cost-savings of RG-NACT in the Dutch
population of ER-positive/HER2-negative breast cancers.
Furthermore, we showed that fully implementing
RG-NACT generates a ~24-fold increase in health
benefits, but requires MRI and personnel capacity to
be increased by 5- and ~20-fold. In the Netherlands,
personnel capacity is likely to be sufficient for a full
implementation scenario, but MRI utilization needs
to be intensified.Abbreviations
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